AstraZeneca to increase spend at Virginia manufacturing facility to $4.5 billion

10 October 2025

UK pharma major AstraZeneca (LSE: AZN) announced that it will now invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500 million to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments.

This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at Rivanna Futures in Albemarle County and is expected to create approximately 3,600 direct and indirect jobs, powering economic growth and Virgina’s leadership at the forefront of life sciences innovation.

AstraZeneca adds to a slew of drugmakers that have pledged multi-billion-dollar US commitments this year, under threat of hefty pharmaceutical tariffs from President Donald Trump. Several companies began to trickle out specific production plans after Trump last month promised a 100% tariff on all branded or patented products, unless their developer was building a manufacturing facility in the US.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK